Loading clinical trials...
Loading clinical trials...
Sorafenib for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3-ITD Positive Acute Myeloid Leukemia
Conditions
Interventions
Sorafenib
Locations
1
China
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Start Date
June 20, 2015
Primary Completion Date
July 21, 2018
Completion Date
August 10, 2019
Last Updated
August 26, 2019
NCT05436418
NCT06285890
NCT07101588
NCT06093867
NCT04146870
NCT06220162
Lead Sponsor
Nanfang Hospital, Southern Medical University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions